Last Updated : May 6, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Uplizna | inebilizumab | Neuromyelitis optica spectrum disorders (NMOSD) | Reimburse with clinical criteria and/or conditions | Active | ||
| Brineura | cerliponase alfa | Neuronal Ceroid Lipofuscinosis Type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
| Oxervate | cenegermin | Neurotrophic keratitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Grastofil | Filgrastim | Neutropenia | List with clinical criteria and/or conditions | Complete | ||
| Neulasta | Pegfilgrastim | Neutropenia | List with clinical criteria and/or conditions | Complete | ||
| Lynparza | Olaparib | Newly Diagnosed OC | Reimburse with clinical criteria and/or conditions | Complete | ||
| Treanda | Bendamustine hydrochloride | Non-Hodgkin Lymphoma and Mantle Cell Lymphoma | Reimburse | Complete | ||
| Erleada | Apalutamide | non-metastatic castrate resistant prostate cancer (nm-CRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Nubeqa | Darolutamide | non-metastatic castration resistant prostate cancer (nmCRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xtandi | Enzalutamide | Non-metastatic castration-resistant prostate cancer (nm-CRPC) | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 6, 2024